M. Schütte

Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial.

W. Brugger, G. Romieu, P. Fargeot, 2007, Critical reviews in oncology/hematology.

FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients

M. Lux, M. Beckmann, P. Fasching, 2014, BMC Cancer.

Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial.

R. Kreienberg, R. Souchon, R. Voigtmann, 1994, Seminars in oncology.

Anti-thyroid peroxidase antibodies are associated with the absence of distant metastases in patients with newly diagnosed breast cancer

T. Löning, D. Roggenbuck, J. Farahati, 2012, Clinical chemistry and laboratory medicine.

Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis.

J. Blohmer, G. von Minckwitz, C. Jackisch, 2002, Clinical breast cancer.

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.

J. Blohmer, G. von Minckwitz, C. Jackisch, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients

M. Lux, M. Beckmann, P. Fasching, 2014, BMC Cancer.

Clinical response by palpation during primary systemic therapy with four dose-dense cycles doxorubicin and docetaxel in patients with operable breast cancer: further results from a randomised controlled trial.

M. Schumacher, Christin Müller, G. von Minckwitz, 2007, European journal of cancer.

Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)

M. Schutte, C. Bokemeyer, N. Harbeck, 2009, Investigational New Drugs.

Abstract PD07-02: Anticancer activity of letrozole plus zoledronic acid as neoadjuvant therapy for postmenopausal patients with breast cancer: FEMZONE trial results

M. Lux, M. Beckmann, P. Fasching, 2012 .